| Identification | Back Directory | [Name]
4-isopropoxy-N-(2-methylquinolin-8-yl)benzamide | [CAS]
892711-75-0 | [Synonyms]
CDN1163
4-isopropoxy-N-(2-methylquinolin-8-yl)benzamide
N-(2-methylquinolin-8-yl)-4-propan-2-yloxybenzamide
4-(1-Methylethoxy)-N-(2-methyl-8-quinolinyl)benzamide
Benzamide, 4-(1-methylethoxy)-N-(2-methyl-8-quinolinyl)- | [Molecular Formula]
C20H20N2O2 | [MDL Number]
MFCD07177494 | [MOL File]
892711-75-0.mol | [Molecular Weight]
320.39 |
| Chemical Properties | Back Directory | [Melting point ]
87 - 89°C | [storage temp. ]
2-8°C | [solubility ]
Soluble in DMSO (>25 mg/ml) | [form ]
powder | [color ]
white to beige | [Stability:]
Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
CDN1163 (892711-75-0) is an allosteric activator of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA).1,2? It lowered fasting glucose levels, improved glucose tolerance, and ameliorated hepatitis steatosis in ob/ob mice.1?? CDN1163 also rescued neurons from ER-stress-induced cell death in vitro and displayed significant efficacy in a rat 6-hydroxydopamine (6-OHDA) model of Parkinson’s disease.2 It reduced age-related muscle atrophy and weakness in a C57BL/6J mice.3? CDN1163 decreased inflammatory cytokines and chemokines and attenuated mitochondrial dysfunction in Influenza A infected H1395 cells.4 | [Uses]
4-(1-Methylethoxy)-N-(2-methyl-8-quinolinyl)benzamide is an allosteric activator that increases Ca2+-ATPase activity and Ca2+ uptake by ER microsomes. 4-(1-Methylethoxy)-N-(2-methyl-8-quinolinyl)benzamide may have therapeutic potential for treating type-2 diabetes and metabolic dysfunction. | [Definition]
ChEBI: CDN1163 is a secondary carboxamide resulting from the formal condensation of the carboxy group of 4-isopropoxybenzoic acid with the primary amino group of 2-methylquinolin-8-amine. An allosteric activator of sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA). It has a role as a SERCA activator. It is a member of quinolines, a secondary carboxamide and an aromatic ether. | [Biochem/physiol Actions]
CDN1163 is an allosteric activator of sarco/ endoplasmic reticulum Ca2+-ATPase (SERCA) that potently lowered fasting blood glucose, improved glucose tolerance and ameliorated hepatosteatosis in ob/ob mice. Additionally CDN1163 induces significant reduction in adipose tissue weight with no change in lean mass in ob/ob mice. CDN1163 has no effect on glucose levels or body weight in lean control mice. | [storage]
Store at RT | [References]
Kang et al. (2016), Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders; J. Biol. 291 5185
Dahl (2017), A new target for Parkinson’s disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats; Bioorg. Med. Chem. 25 53
Qaisar et al. (2020), Restoration of Sarcoplasmic Reticulum Ca2+ ATPase (SERCA) Activity Prevents Age-Related Muscle Atrophy and Weakness in Mice; Int. J. Mol. Sci. 22 37
Peng et al. (2021), Sarco/Endoplasmic Reticulum Ca2+ Transporting ATPase (SERCA) Modulates Autophagic, Inflammatory, and Mitochondrial Responses during Influenza A Virus Infection in Human Lung Cells; J. Virol. 1128/JVI00217-21 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|